AbbVie Competitors

Stocks . Germany . 
Stock . AbbVie Inc
4AB Stock  EUR 173.96  1.94  1.10%   
AbbVie Inc competes with Air New, WIZZ AIR, Wizz Air, Norwegian Air, and Westinghouse Air; as well as few others. The company classifies itself under Healthcare sector and is part of Drug Manufacturers - Major industry. Analyzing AbbVie competition allows you to expand the diversification possibilities of your existing portfolios and to get a better perspective on locking in new positions. Investors sometimes prefer comparable analysis of AbbVie to its intrinsic valuation because they are able to contrast its competitors on a relative basis. Check out AbbVie Correlation with its peers.
You can use the Comparative Equity Analysis module to analyze the advantages of investing in your portfolio's related equities across multiple sectors and thematic ideas. Please use the input box below to enter symbols for particular investments you would like to analyze. With the equity comparison module, you can estimate the relative effect of AbbVie competition on your existing holdings.
  
Specify up to 10 symbols:
Hype
Prediction
LowEstimatedHigh
171.75173.96176.17
Details
Intrinsic
Valuation
LowRealHigh
143.40145.61191.36
Details
Naive
Forecast
LowNextHigh
185.16187.37189.57
Details
Bollinger
Band Projection (param)
LowerMiddle BandUpper
152.92167.34181.76
Details

AbbVie Competition Correlation Matrix

Typically, diversification allows investors to combine positions across different asset classes to reduce overall portfolio risk. Correlation between AbbVie and its competitors represents the degree of relationship between the price movements of corresponding stocks. A correlation of about +1.0 implies that the price of AbbVie and its corresponding peer move in tandem. A correlation of -1.0 means that prices move in opposite directions. A correlation of close to zero suggests that the price movements of assets are uncorrelated; in other words, the historical price movement of AbbVie Inc does not affect the price movement of the other competitor.
Click cells to compare fundamentals   Check Volatility   Backtest Portfolio
High positive correlations   
WI2
+ 0.9
WI20
VTE1
+ 0.72
WB2
VTE1
+ 0.69
FA2
WB2
+ 0.66
FA2
WB2
+ 0.55
WI2
NWC
+ 0.52
BZU
  
High negative correlations   
VTE1
- 0.22
NWC
WB2
- 0.22
NWC
NWC
- 0.1
WI2
NWC
- 0.07
WI20
PSAN
- 0.02
WI20

Risk-Adjusted Indicators

There is a big difference between AbbVie Stock performing well and AbbVie Company doing well as a business compared to the competition. There are so many exceptions to the norm that investors cannot definitively determine what's good or bad unless they analyze AbbVie's multiple risk-adjusted performance indicators across the competitive landscape. These indicators are quantitative in nature and help investors forecast volatility and risk-adjusted expected returns across various positions.
All Fundamental Data

AbbVie Competitive Analysis

The better you understand AbbVie competitors, the better chance you have of utilizing it as a position in your portfolios. From an individual investor's perspective, AbbVie's competitive analysis can cover a whole range of metrics. Some of these will be more critical depending on who you are as an investor and how you react to market volatility. However, if you are locking your investment sandscape to a long-term horizon, comparing the fundamental indicator across AbbVie's competition over several years is one of the best ways to analyze its investment potential.
    
 Better Than Average     
    
 Worse Than Peers    View Performance Chart
4AB BZU WI20 FA2 WI2 NWC WB2 PSAN VTE1
 1.10 
 173.96 
AbbVie
 3.33 
 0.31 
Air
 1.06 
 3.80 
WIZZ
 0.59 
 33.60 
FORWARD
 0.64 
 15.42 
Wizz
 1.03 
 0.96 
Norwegian
 0.93 
 190.75 
Westinghouse
 0.93 
 21.80 
PSI
 1.10 
 9.20 
ASURE
Market Volatility
(90 Days Market Risk)
Very steady
Abnormally volatile
Unstable
Not too volatile
Somewhat reliable
Extremely Dangerous
Very steady
Very steady
Somewhat reliable
Market Performance
(90 Days Performance)
Very Weak
Weak
Very Weak
Modest
Weak
Weak
Solid
Modest
OK
Odds of Financial Distress
(Probability Of Bankruptcy)
Low
Low
Quite High
About Average
About Average
Quite High
Low
Low
About Average
Current Valuation
(Equity Enterprise Value)
Over Valued
Over Valued
Over Valued
Over Valued
Over Valued
Over Valued
Under Valued
Fairly Valued
Over Valued
Buy or Sell Advice
(Average Analysts Consensus)
Not Available
Not Available
Not Available
Not Available
Not Available
Not Available
Not Available
Not Available
Not Available
Trade Advice
(90 Days Macroaxis Advice)
Strong Sell
Strong Sell
Strong Sell
Strong Sell
Strong Sell
Strong Sell
Strong Buy
Strong Sell
Strong Sell
Current Ratio
1.04
N/A
N/A
N/A
N/A
0.52
1.35
N/A
N/A
Net Asset
138.81 B
8.35 B
N/A
N/A
5.36 B
18.83 B
18.52 B
284.12 M
419.91 M
Profit Margin
0.2
N/A
-0.17
N/A
N/A
0.0533
0.0757
0.0503
N/A
EBITDA
24.17 B
N/A
(356.48 M)
N/A
(105.7 M)
3.69 B
1.47 B
37.5 M
10.49 M
Operating Margin
0.39
N/A
-0.14
N/A
N/A
-0.0316
0.13
0.0858
N/A
Current Valuation
331.38 B
4.13 B
N/A
N/A
5.62 B
1.03 B
21.22 B
328.4 M
180.55 M
Price To Book
18.07
1.58
N/A
N/A
10.25
1.65
1.87
3.12
1.13
Five Year Return
3.39
N/A
N/A
N/A
N/A
N/A
0.34
N/A
N/A
Beta
0.58
N/A
2.07
N/A
N/A
1.05
1.47
0.69
N/A
Number Of Employees
50 K
19
4.71 K
N/A
N/A
43
27 K
2.26 K
N/A
Shares Outstanding
1.77 B
N/A
413.07 M
N/A
N/A
931.59 M
180.35 M
15.54 M
N/A
Cash Flow From Operations
24.94 B
N/A
N/A
N/A
370.6 M
139.1 M
1.04 B
38.75 M
13.67 M
Annual Yield
0.038
0.22
N/A
N/A
N/A
N/A
0.0066
0.016
N/A
Total Debt
59.13 B
1.59 B
N/A
N/A
1.04 B
3.98 B
3.75 B
20.93 M
30.8 M
Return On Equity
0.72
N/A
-3.43
N/A
N/A
0.27
0.0629
0.14
N/A
Z Score
2.4
0.6
N/A
N/A
3.0
N/A
2.4
10.8
2.4
Return On Asset
0.0991
N/A
-0.0596
N/A
N/A
-0.018
0.0362
0.0491
N/A
Book Value Per Share
9.75
N/A
0.68
N/A
N/A
4.52
55.75
7.17
N/A
Total Asset
138.81 B
8.35 B
N/A
N/A
5.36 B
18.83 B
18.52 B
284.12 M
419.91 M
Target Price
127.01
N/A
N/A
N/A
N/A
0.4
93.89
36.0
N/A
Last Dividend Paid
5.71
0.11
N/A
N/A
N/A
N/A
0.6
0.4
N/A
Debt To Equity
N/A
N/A
N/A
N/A
N/A
N/A
50.7
N/A
N/A
Shares Owned By Institutions
71.51
N/A
N/A
N/A
N/A
38.96
94.77
32.36
N/A
Market Capitalization
256.3 B
2.12 B
3.23 B
N/A
6.05 B
952.51 M
17.5 B
382.2 M
151.35 M
Price To Earning
22.27
N/A
N/A
N/A
N/A
1.75
29.19
N/A
N/A
Price To Earnings To Growth
1.29
0.87
N/A
N/A
1.6
N/A
N/A
N/A
1.29
Price To Sales
4.72
0.42
N/A
N/A
1.26
0.0669
2.11
1.34
1.87
Net Income
11.84 B
N/A
N/A
N/A
(631.8 M)
1.87 B
633 M
15.84 M
(14.47 M)
Earnings Per Share
6.25
N/A
-1.58
N/A
N/A
0.01
3.26
0.97
N/A
Shares Owned By Insiders
0.12
N/A
N/A
N/A
N/A
20.38
4.34
35.22
N/A
Revenue
58.05 B
N/A
3.48 B
N/A
1.66 B
5.07 B
8.36 B
248.39 M
95.83 M
Cash And Equivalents
5.23 B
N/A
N/A
N/A
N/A
790.84 M
512.87 M
N/A
N/A
Cash Per Share
3.54
N/A
N/A
N/A
N/A
20.43
3.15
N/A
N/A
Gross Profit
41.53 B
N/A
73.3 M
N/A
N/A
1.33 B
2.58 B
53.92 M
N/A
Day Typical Price
173.48
0.31
3.8
33.6
15.4
0.96
190.0
21.73
9.2
Accumulation Distribution
1.51
0.0323
N/A
N/A
0.0148
9.35
0.54
50.45
N/A
Market Facilitation Index
0.0079
0.01
N/A
N/A
0.23
0.0
0.0843
0.0
N/A
Daily Balance Of Power
(1.35)
1.0
9.2 T
(9,223,372,036,855)
(0.43)
(1.00)
0.5932
1.0
9.2 T
Period Momentum Indicator
(1.94)
0.01
0.04
(0.20)
(0.10)
(0.01)
1.75
0.2
0.1
Rate Of Daily Change
0.99
1.03
1.01
0.99
0.99
0.99
1.01
1.01
1.01
Day Median Price
173.24
0.31
3.8
33.6
15.4
0.97
189.63
21.7
9.2
Price Action Indicator
(0.25)
0.01
0.02
(0.10)
(0.03)
(0.01)
2.0
0.2
0.05
Relative Strength Index
31.08
57.74
74.57
49.02
74.57
56.51
74.97
42.5
55.55
Coefficient Of Variation
56344.72
2681.95
6598.41
1584.44
10254.8
2456.79
404.18
1258.84
930.88
Mean Deviation
1.22
0.9162
2.61
2.86
2.74
2.47
1.01
0.9129
1.95
Jensen Alpha
0.0183
0.0143
(0.11)
0.158
0.0479
0.097
0.2093
0.0655
0.0827
Total Risk Alpha
(0.37)
(0.23)
(0.56)
(0.48)
(0.59)
(0.43)
0.1045
(0.12)
(0.18)
Sortino Ratio
(0.05)
(0.02)
(0.03)
0.043
(0.03)
(0.0004)
0.26
(0.02)
0.055
Downside Variance
6.9
12.61
8.8
12.15
10.81
16.86
0.6802
2.19
9.94
Standard Deviation
2.19
1.73
3.6
4.55
3.68
3.34
1.42
1.27
2.9
Kurtosis
19.12
1.05
2.09
14.83
1.23
1.28
8.39
2.04
2.45
Potential Upside
3.16
3.45
7.14
5.19
6.94
5.38
2.57
2.26
5.16
Treynor Ratio
0.0319
0.1732
0.0359
0.2964
(0.15)
0.5566
0.3287
0.4538
0.176
Maximum Drawdown
19.0
6.9
18.74
30.84
19.13
16.03
9.23
7.62
15.12
Variance
4.81
2.98
12.97
20.74
13.51
11.15
2.02
1.62
8.39
Market Risk Adjusted Performance
0.0419
0.1832
0.0459
0.3064
(0.14)
0.5666
0.3387
0.4638
0.186
Risk Adjusted Performance
0.0079
0.0341
0.0195
0.0566
0.0154
0.0388
0.1938
0.0647
0.0895
Skewness
(2.78)
0.0957
0.9792
2.69
0.427
(0.64)
2.07
0.1759
0.238
Semi Deviation
2.58
1.23
2.8
3.08
3.24
3.26
0.5121
1.1
2.4
Information Ratio
(0.06)
(0.04)
(0.02)
0.0329
(0.03)
(0.0005)
0.1507
(0.03)
0.0599
Value At Risk
(2.05)
(3.33)
(5.41)
(4.94)
(4.24)
(4.85)
(1.14)
(1.79)
(4.05)
Expected Short fall
(1.19)
(3.42)
(3.37)
(3.54)
(3.15)
(2.95)
(1.38)
(1.11)
(2.53)
Downside Deviation
2.63
3.55
2.97
3.49
3.29
4.11
0.8247
1.48
3.15
Semi Variance
6.67
1.51
7.84
9.49
10.48
10.63
0.2623
1.21
5.75

AbbVie Competition Performance Charts

Five steps to successful analysis of AbbVie Competition

AbbVie's competitive analysis is the process of researching and evaluating its competitive landscape. It provides an understanding of the strengths, weaknesses, opportunities, and threats (SWOT) faced by AbbVie Inc in relation to its competition. AbbVie's competition analysis typically involves several steps, including:
  • Identifying the key players in the market: This involves identifying the major competitors of AbbVie in the market, both direct and indirect, as well as new entrants and disruptive technologies.
  • Assessing the strengths and weaknesses of each competitor: This involves evaluating each competitor's strengths and weaknesses in areas such as product offerings, market share, brand recognition, financial performance, and distribution channels.
  • Understanding the competitive environment: This involves evaluating the regulatory environment, economic conditions, and other factors that may impact AbbVie's competitive landscape.
  • Identifying opportunities and threats: This involves using the information gathered during the analysis to identify opportunities and threats to AbbVie Inc, and developing a strategy to address them.
  • Evaluating the competitive landscape: This involves understanding the competitive dynamics of the market, such as pricing, marketing, and distribution strategies, as well as analyzing the competitive advantage of each competitor.
Competitive analysis is an essential tool for businesses to stay ahead of the competition and can be used to inform decision-making and strategy development. By understanding the competitive landscape and staying informed about the activities of competitors, a company can make more informed decisions and improve its overall performance.

Complement your AbbVie position

In addition to having AbbVie in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.

Did You Try This Idea?

Run Mid Cap ETFs Thematic Idea Now

Mid Cap ETFs
Mid Cap ETFs Theme
ETF themes focus on helping investors to gain exposure to a broad range of assets, diversify, and lower overall costs. The Mid Cap ETFs theme has 70 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Mid Cap ETFs Theme or any other thematic opportunities.
View All  Next Launch

Additional Information and Resources on Investing in AbbVie Stock

When determining whether AbbVie Inc is a strong investment it is important to analyze AbbVie's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact AbbVie's future performance. For an informed investment choice regarding AbbVie Stock, refer to the following important reports:
How To Invest In AbbVie
Details
Is AbbVie Stock a good investment?
Details
What is AbbVie's Net Worth?
Details
Largest Biotechnology Companies
View
Largest Pharmaceuticals, Biotechnology & Life Sciences Companies
View
Check out AbbVie Correlation with its peers.
You can also try the Portfolio Center module to all portfolio management and optimization tools to improve performance of your portfolios.
Altman
Z Score
Details
Intrinsic
Valuation
Details
Financial
Analysis
Details
Buy or Sell
Advice
Details
Technical
Analysis
Details
Please note, there is a significant difference between AbbVie's value and its price as these two are different measures arrived at by different means. Investors typically determine if AbbVie is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, AbbVie's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2024 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY